The medicines regulator has approved the first treatment using artificial antibodies to prevent and fight Covid-19.- Ronapreve can be used to treat symptoms of acute infection after successful clinical trials.
- Sajid Javid, the Health Secretary, expressed a great hope to make it available to patients on the NHS.
The medicines regulator has approved the first treatment in the U.K. using artificial antibodies to prevent and fight Covid-19, says The Guardian.
Raising Hopes
Regeneron, the US biotech company, has acquired support from the MHRA and clinical trials have indicated that Covid and hospitalization risks or symptoms have been decreased in extreme situations when administered soon after exposure.
Sajid Javid, the Health Secretary, described the drug’s approval as “Fantastic News” and expressed hope that it may be made available to patients on the NHS.
Javid added, “ This treatment will be a significant addition to our armory to tackle Covid-19 – in addition to our world-renowned vaccination program and life-saving therapeutics dexamethasone and tocilizumab.
“We are pleased to announce the approval of another therapeutic treatment that can help save lives and protect against Covid-19,” said Dr. Samantha Atkinson, interim chief quality and access officer at the Medicines and Healthcare Products Regulatory Agency.
“Ronapreve is the first of its kind for the treatment of Covid-19 and, after a meticulous assessment of the data by our expert scientists and clinicians, we are satisfied that this treatment is safe and effective. With no compromises on quality, safety, and efficacy, the public can trust that the MHRA has conducted a robust and thorough assessment of all the available data.”
Ronapreve
Ronapreve , the U.K.’s first monoclonal antibody combination product licensed to prevent and treat acute viral infection. Monoclonal antibodies are artificial proteins that function in the immune system similar to the typical human immune system.
According to the MHRA, the medicine is administered by injection or infusion. It operates at the lining of the respiratory system, where it binds strongly to the virus and stops it from obtaining access to the cells.
Did you subscribe to our daily newsletter?
It’s Free! Click here to Subscribe!
Source: The Guardian
